X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

BCAB

Closed

Bioatla inc

0.3905
-0.0055 (-1.39%)
Last Update: 01 Jul 2025 23:18:00
Yesterday: 0.396
Day's Range: 0.39 - 0.4088
Send
When Written:
 
2.68
BioAtla Inc. is a clinical-stage biotechnology company that develops novel antibody-based therapeutics for cancer and other diseases. The company's proprietary technology platform, called the Conditionally Active Biologics (CAB) platform, allows for the creation of highly specific and potent antibodies that target tumor cells while sparing healthy cells. BioAtla's lead product candidate, BA3011, is a CAB antibody that targets HER2-expressing tumors and is currently in Phase 1 clinical trials. Other product candidates in the company's pipeline include CAB antibodies targeting PD-L1, CD19, and CD38. BioAtla was founded in 2007 and is headquartered in San Diego, California.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.58
X